The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Uniphar Durbin Ireland Limited Durbin or the Company and TFF Pharmaceuticals Inc Nasdaq TFFP have jointly announced the launch of an Expanded Access Program EAP for TFFVORI
Ionis Pharmaceuticals Inc Nasdaq IONS has successfully completed the enrollment phase of the Phase CARDIOTTRansform cardiovascular outcomes study for eplontersen an investigational drug targeting transthyretinmediated amyloid cardiomyopathy ATTRCM
Marinus Pharmaceuticals Inc Nasdaq MRNS has received approval from the European Commission EC for the oral suspension medication ZTALMY ganaxolone
IO Biotech Nasdaq IOBT has recently announced the initiation of an investigatorinitiated trial in collaboration with the University of California Davis Comprehensive Cancer Center
NS Pharma Inc announced today that the US Food Drug Administration FDA has granted Breakthrough Therapy Designation to NSNCNP an investigational candidate developed for patients with Duchenne muscular dystrophy amenable to exon skipping therapy
Genenta Science NASDAQ GNTA has provided an update on its clinicalstage immunooncology IO efforts focusing on the development of Temferon a cellbased platform aimed at providing safe and durable treatments for solid tumors
Peptomyc SL is a specialized biotech company dedicated to developing protein therapeutics for cancer treatment The company has received full approval for its Phase b clinical trial which aims to evaluate the combination of OMO a groundbreaking MYC in...
Celularity Inc Nasdaq CELU and Versa Ophthalmics LLC have entered into an exclusive US commercialization agreement according to their joint announcement Versa Ophthalmics a company based in Tampa FL specializes in delivering complete ocular pointofca...
Reece Pharmaceuticals Ltd ASX RCE FSE RQ has made an exciting announcement regarding the progress of its Phase III clinical trial for a new class of synthetic antiinfectives targeting urinary tract infections UTIs
MyoPax a biotechnology company has received Orphan Drug Designation from the US Food and Drug Administration FDA for its advanced regenerative cell therapy aimed at treating ExstrophyEpispadias Complex EEC
